IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ — On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation.
NTS071 is an oral small molecule allosteric reactivator targeting p53 Y220C with a novel scaffold. It selectively binds to the p53 Y220C mutant protein, improving its thermal stability, thereby enhancing the mutant protein's ability to bind with DNA and restoring its transcriptional activity as well as tumor-suppressing function.
NTS071 was discovered by leveraging Nutshell's proprietary AI driven allosteric small molecule drug discovery platform ALLOSTAR™. NTS071 demonstrated potential Best-in-Class preclinical properties for its target. NTS071 achieved a picomolar-level biochemical activity which is 20 folds more potent than the competitive compound PC14586. Additionally, NTS071 shows better stability in both liver microsomes and hepatocytes across different species and exhibits lower in vivo clearance rates and higher oral exposure s in preclinical PK studies across all tested species compared to PC14586. NTS071 has relatively lower plasma protein binding and higher free fraction than PC14586, which is beneficial for in vivo efficacy. NTS071 also addresses the CYP3A4 inhibition issue of PC14586, presenting lower risks for potential drug – drug interactions. NTS071 further displays a large safety window by exhibiting an overall good safety profile in non-clinical toxicology studies.
NTS071 exhibited dose-dependent in vivo anti-tumor activity in multiple CDX and PDX models harboring p53 Y220C mutation, spanning a number of different cancer types, including ovarian cancer, lung cancer, gastric cancer, breast cancer, head and neck cancer, esophageal cancer, pancreatic cancer, and bladder cancer, etc. Therefore, NTS071 has the potential to be a tumor-agnostic therapy for patients carrying p53 Y220C mutation. Compared to PC14586, NTS071 has shown significantly lower effective doses or better efficacy at the same dose level in all comparative preclinical in vivo studies, implying that NTS071 may overcome the limitation of its competitor that has a higher dose requirement, thereby potentially achieving better therapeutic effects. NTS071 is anticipated to initiate Phase 1 clinical trial in second half of 2025 and expected to benefit patients with solid tumors harboring this mutation.
p53 Y220C mutation is widespread in various solid tumors. Studies show that there are 125,000 to 150,000 new cases worldwide annually, representing a significant market potential. Enriched with years of accumulated experience with its proprietary computation-based allosteric drug development technology and breakthrough innovation capabilities at Nutshell Therapeutics, NTS071 has the potential to stand out among peer products and become the most competitive drug molecule for this target.
The NTS071 Poster presented at the EORTC-NCI-AACR (ENA) 2024 conference can be accessed here: http://allonutshell.com/images/109_Nutshell-NTS071-ENA-2024-Poster.pdf
About Nutshell
Nutshell Therapeutics (http://www.allonutshell.com/) is an innovative biotech company developing small molecule drugs for historically challenging targets employing allosteric mechanisms. Founded by Professor Zhang Jian, one of the leading figures in the allosteric drug discovery field globally, the company has established an integrated R&D platform with diverse dry and wet lab functions and has focused intensely on allosteric small – molecule drug discovery and development for many years. The company has successfully raised more than US$75 million from various well-known venture capitals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
123Invent Inventor Develops Improved Bra for Curvier Women
PITTSBURGH, June 9, 2025 /PRNewswire/ — 'As a curvier woman, I hated the discomfort associated with wearing a traditional bra. I wanted to create a more comfortable option for me, my daughter, and other women with curves,' said an inventor, from Wagga, NSW, Australia, 'so I invented the CroBra (by Char). My design provides added comfort and support, and the improved sizing guide helps you select the right size.' The patent-pending invention provides an improved bra option for curvier women. In doing so, it prevents the bra from riding up and digging into the skin. It also helps prevent bulging. As a result, it increases comfort and support. Additionally, the invention features a unique design that is easy to wear. The CroBra (by Char) is currently available for licensing or sale to manufacturers or marketers. For more information, visit Or contact Lidia Ilievski at 045-720-0678 or email info@
Malaysian Reserve
8 hours ago
- Malaysian Reserve
FirstEnergy Announces Proposed Offering of $950 Million of Convertible Senior Notes Due 2029 and $850 Million of Convertible Senior Notes Due 2031
AKRON, Ohio, June 9, 2025 /PRNewswire/ — FirstEnergy Corp. (NYSE: FE) ('FirstEnergy') announced today that it intends to offer, subject to market and other conditions, $950 million aggregate principal amount of convertible senior notes due 2029 (such series, the '2029 Notes') and $850 million aggregate principal amount of convertible senior notes due 2031 (such series, the '2031 Notes' and, together with the 2029 Notes, the 'Notes') in a private placement under the Securities Act of 1933, as amended (the 'Securities Act'). FirstEnergy also intends to grant to each of the initial purchasers of the Notes an option to purchase, within a 13-day period from, and including, the date on which the convertible notes are first issued, up to an additional $150 million aggregate principal amount of the 2029 Notes and an additional $150 million aggregate principal amount of the 2031 Notes. FirstEnergy intends to use the net proceeds from the offering of the Notes for (i) the repurchase of all or a portion of the $1.5 billion aggregate principal amount outstanding of its 4.00% convertible senior notes due May 1, 2026, (ii) the repayment, redemption or refinancing of existing indebtedness, (iii) general corporate purposes, or (iv) any combination of the foregoing. FirstEnergy's management will have broad discretion in determining how the net proceeds from the offering will be used. The Notes will be unsecured and unsubordinated obligations of FirstEnergy, and will be convertible at the option of the holders of each series of Notes upon satisfaction of certain conditions and during certain periods. Interest will be payable semiannually in arrears. FirstEnergy will settle conversions of the Notes by paying cash up to the aggregate principal amount of the convertible notes to be converted and paying or delivering, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The interest rate, initial conversion rate and other terms of each series of Notes will be determined at the pricing of the offering. The offering is being made to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. Any offers of the Notes will be made only by means of a private offering memorandum. None of the Notes or any shares of the common stock issuable upon conversion of the Notes have been or are expected to be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any shares of common stock issuable upon conversion of the Notes, nor will there be any sale of the Notes or any such shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About FirstEnergy Corp. FirstEnergy is dedicated to integrity, safety, reliability and operational excellence. Its electric distribution companies form one of the nation's largest investor-owned electric systems, serving more than 6 million customers in Ohio, Pennsylvania, New Jersey, West Virginia, Maryland and New York. The company's transmission subsidiaries operate approximately 24,000 miles of transmission lines that connect the Midwest and Mid-Atlantic regions. Follow FirstEnergy online at and on X @FirstEnergyCorp. Forward-Looking Statements: This news release includes forward-looking statements based on information currently available to management and unless the context requires otherwise, references to 'we,' 'us,' 'our' and 'FirstEnergy' refers to FirstEnergy Corp. and its subsidiaries. Such statements are subject to certain risks and uncertainties and readers are cautioned not to place undue reliance on these forward-looking statements. These statements typically contain, but are not limited to, the terms 'anticipate,' 'potential,' 'expect,' 'forecast,' 'target,' 'will,' 'intend,' 'believe,' 'project,' 'estimate,' 'plan' and similar words. These statements include declarations regarding management's intents, beliefs and current expectations, including statements regarding FirstEnergy Corp.'s current expectations and beliefs as to the pricing and closing of the convertible notes offering and use of the proceeds thereof. These forward-looking statements are not guarantees of future performance and they are based on management's expectations that involve or rely on a number of known and unknown risks, uncertainties and other factors that are difficult to predict or are beyond our control, and reflect management's beliefs and assumptions based on information available at the time the statements are made. FirstEnergy Corp. cautions you that actual results may differ materially from those expressed, implied or forecast by the forward-looking statements. Risks that may cause these forward-looking statements to be inaccurate or incorrect include, among others whether we will be able to consummate the convertible notes offering; the final terms of the convertible notes offering; the satisfaction of customary closing conditions with respect to the convertible notes offering; prevailing market conditions; the anticipated use of net proceeds of the convertible notes offering which could change as a result of market conditions or for other reasons; and the risks and other factors discussed from time to time in our Securities and Exchange Commission filings, including, but not limited to, the most recent Annual Report on Form 10-K, and any subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. FirstEnergy Corp. expressly disclaims any obligation to update or revise, except as required by law, any forward-looking statements contained herein or in the information incorporated by reference as a result of new information, future events or otherwise.
Malaysian Reserve
8 hours ago
- Malaysian Reserve
Newlyweds Say 'I Do' to Love, But 'I Don't' to Estate Planning: 42% of Couples Haven't Created One
New Survey from Trust & Will Finds Marriage Sparks Conversations About Legacy—But Many Delay Estate Planning for a Decade or More SAN DIEGO, June 9, 2025 /PRNewswire/ — Love is in the air this wedding season, but financial protection isn't. A new report from Trust & Will exposes a critical disconnect between love, life milestones, and long-term planning. Despite saying 'till death do us part,' 42% of married Americans have no estate plan whatsoever – leaving their spouses and families financially vulnerable. With over two million weddings expected for 2025 – with 225,000 expected in June alone and well over 600,000 in summer1 – the timing couldn't be more critical. Yet, the survey reveals that even marriage, one of life's most significant milestones, fails to prompt immediate action on estate planning. 'When I got married, my wife and I realized we had no will, no healthcare directive, nothing. It was a wake-up call,' said Cody Barbo, Co-founder and CEO of Trust & Will. 'That realization inspired the very foundation of this company. Marriage is about building a life together, and an estate plan is part of securing that life.' The national survey of 750 Americans (evenly split among single, engaged, and married respondents) uncovered deep gaps in awareness, confidence, and estate planning behavior. The Procrastination Problem: While married individuals are nearly 4x more likely than engaged couples to have a will (44% vs. 12%), nearly half still have no estate plan at all. Of those who do plan, 30% waited 9 years or more after marriage to act; 38% of engaged respondents say marriage motivated them to consider estate planning. Only 19% of married couples create an estate plan within their first four years together. Overcoming the Engagement Disconnect: 38% of engaged couples say marriage motivates them to consider estate planning, but only 12% actually have a will. 50% admit they lack basic estate planning knowledge. Only 15% have a healthcare directive, and 9% don't know what one is. 37% haven't even considered naming an executor or trustee for their estate. The Gender and Generational Divide Millennials and Gen Z show strong intent (40%+ plan to create estate plans within 5 years) but they face barriers like cost, time, and lack of understanding. Men are 3x more likely to have a trust than women. Women are more likely to feel overwhelmed by estate planning and 38% more likely to feel financially insecure. Despite 67% of respondents citing 'being overwhelmed' as their primary barrier, estate planning can be completed in hours. Without planning, surviving spouses can face: A lengthy and expensive probate process. Inability to make critical medical decisions. Freezing of financial accounts. Disputes among family members over assets. Potential tax issues. 'A wedding is more than a celebration, it's a pledge to protect one another,' said Barbo. 'Creating an estate plan is one of the most meaningful expressions of love. It offers your partner peace of mind, security, and the clarity that comes from knowing your wishes are understood and honored.' To read the full report, please visit: About Trust & WillFounded in 2017, Trust & Will is the leading digital estate planning platform in the U.S., trusted by over one million individuals and families. Our simple, secure, and attorney-approved online solutions help Americans easily create wills, trusts, healthcare directives, and other essential estate planning documents tailored to state-specific laws. With a focus on easy access and a guided experience, we're transforming how families plan for the future and protect their legacies. Our platform supports 20,000+ financial advisors, along with 150+ enterprise partners and financial institutions — including AARP, Fifth Third Bank, LPL Financial, UBS, and USAA. We empower professionals to integrate estate planning into their client services, enabling multi-generational wealth planning. With more than one million users and $100+ billion in self-reported estate assets, Trust & Will is redefining estate planning as a relationship-deepening driver of financial wellness. Recognized for innovation and leadership, Trust & Will has earned spots on the CNBC Disruptor 50, Inc. 5000, and Deloitte Technology Fast 500™ lists. Learn more at Media Contact: Mark LoCastro, Trust & Willpress@ 1 'Here Comes … A Lot of Couples Getting Married,' National Jeweler, June 29, 2022 [source URL]
